quinoline has been researched along with Trypanosomiasis, African in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Basta, A; Biancofiore, I; Ciammaichella, A; D'Amico, M; Ferrigno, F; Fini, I; Gennari, N; Graziani, R; Harper, S; Nardi, V; Ontoria, JM; Paonessa, G; Ponzi, S; Summa, V; Vittoria Orsale, M | 1 |
| Bland, ND; Campbell, RK; Ochiana, SO; Pollastri, MP; Settimo, L | 1 |
2 other study(ies) available for quinoline and Trypanosomiasis, African
| Article | Year |
|---|---|
Optimization of 2-(1H-imidazo-2-yl)piperazines series of Trypanosoma brucei growth inhibitors as potential treatment for the second stage of HAT.
Topics: Cell Survival; Drug Evaluation, Preclinical; Growth Inhibitors; Human Umbilical Vein Endothelial Cells; Humans; Isomerism; Morpholines; Piperazines; Quinolines; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosomiasis, African | 2020 |
Repurposing human PDE4 inhibitors for neglected tropical diseases. Evaluation of analogs of the human PDE4 inhibitor GSK-256066 as inhibitors of PDEB1 of Trypanosoma brucei.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminoquinolines; Binding Sites; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Repositioning; Humans; Molecular Docking Simulation; Neglected Diseases; Phosphodiesterase 4 Inhibitors; Protein Structure, Tertiary; Protozoan Proteins; Quinolines; Structure-Activity Relationship; Sulfones; Trypanosoma brucei brucei; Trypanosomiasis, African | 2015 |